当前位置：
X-MOL 学术
›
Hum. Reprod.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A heterozygous SPRY4 variant identified in female infertility characterized by reduced oocyte potential and early embryonic arrest.
Human Reproduction ( IF 6.0 ) Pub Date : 2024-11-01 , DOI: 10.1093/humrep/deae231 Lingjin Xia,Jiami Huang,Qi Che,Jian Zhang,Zhaofeng Zhang,Yupei Shen,Difei Wang,Yushun Zhong,Suying Liu,Jing Du
Human Reproduction ( IF 6.0 ) Pub Date : 2024-11-01 , DOI: 10.1093/humrep/deae231 Lingjin Xia,Jiami Huang,Qi Che,Jian Zhang,Zhaofeng Zhang,Yupei Shen,Difei Wang,Yushun Zhong,Suying Liu,Jing Du
STUDY QUESTION
Can novel genetic factors contributing to early embryonic arrest in infertile patients be identified, along with the underlying mechanisms of the pathogenic variant?
SUMMARY ANSWER
We identified a heterozygous variant in the SPRY4 (sprouty RTK signaling antagonist 4) in infertile patients and conducted in vitro and in vivo studies to investigate the effects of the variant/deletion, highlighting its critical role in female reproductive health.
WHAT IS KNOWN ALREADY
SPRY4 acts as a negative regulator of receptor tyrosine kinases (RTKs) and functions as a tumor suppressor. Its abnormal expression can lead to recurrent miscarriage by affecting trophoblast function. In mice, Spry4 knockout (KO) leads to craniofacial anomalies and growth defects. A human study links the SPRY4 variant to a male patient with isolated hypogonadotropic hypogonadism (IHH), hypothetically impacting gonadotropin-releasing hormone (GnRH) neurons, and causing reproductive dysfunctions. SPRY4 is thus potentially integral in regulating endocrine homeostasis and reproductive function. To date, no study has reported SPRY4 variants associated with female fertility, and a causal relationship has not been established with functional evidence.
STUDY DESIGN, SIZE, DURATION
Whole-exome sequencing (WES) was performed in 392 infertile women who suffered from primary infertility of unknown reason, and the heterozygous SPRY4 variant were identified in one independent family. The infertile patients presenting were recruited from July 2017 to November 2023.
PARTICIPANTS/MATERIALS, SETTING, METHODS
Women diagnosed with primary infertility were recruited from the Reproduction Center of Zhongshan Hospital, Fudan University. Genomic DNA was extracted from peripheral blood for WES analysis. The SPRY4 variant were identified through WES, in silico analysis, and variant screening. All variants were confirmed by Sanger sequencing. The effects of the variants were investigated in human embryonic kidney (HEK) 293T (HEK293T) cells via western blotting, and in mouse oocytes and embryos through complementary RNA (cRNA) injection, RNA sequencing, fluorescence, absorbance, and RT-qPCR assays. Gene function was further examined in Spry4 KO mice via histology, western blotting, ELISA, and RT-qPCR assays.
MAIN RESULTS AND THE ROLE OF CHANCE
We identified a missense heterozygous pathogenic variant in SPRY4 (GRCh38, GenBank: NM_030964.5, c.157C>T p.(Arg53Trp), rs200531302) that reduces SPRY4 protein levels in HEK293T cells and disrupts the redox system and mitochondrial function in mouse oocyte, and perturbs developmental potential in mouse embryos. These phenotypes could be partially reversed by the exogenous addition of Nrf1 cRNA. Additionally, Spry4-/- mice exhibit ovarian oxidative stress and decreased ovarian function.
LIMITATIONS, REASONS FOR CAUTION
Due to the limited WES data and population, we identified only one family with a SPRY4 mutation. The deeper mechanism and therapeutic strategy should be further investigated through mutant mice and recovery experiment.
WIDER IMPLICATIONS OF THE FINDINGS
Our study has identified a pathogenic variant in SPRY4 associated with early embryonic arrest in humans. These findings enhance our understanding of the role of SPRY4 in early embryonic development and present a new genetic marker for female infertility.
STUDY FUNDING/COMPETING INTEREST(S)
This work was supported by the National Natural Science Foundation of China (82071643 and 82171655) and Natural Science Foundation of Shanghai (22ZR1456200). None of the authors have any competing interests.
TRIAL REGISTRATION NUMBER
N/A.
更新日期：2024-09-30
京公网安备 11010802027423号